Brian Archbold Sells 2,454 Shares of MLAB
MLAB's SVP Operations, Brian Archbold, sold 2,454 shares on June 15, 2026.
Key Points
- Brian Archbold, SVP Operations at MLAB, sold 2,454 shares on June 15, 2026.
- MLAB shares are trading at $104.08 with significant institutional activity.
- Wells Fargo maintained a 'hold' rating with a $94 target, while Evercore ISI held a 'buy' with a $106 target.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 15, 2026, Brian Archbold, the Senior Vice President of Operations at MLAB, sold 2,454 shares of the company. This insider transaction is part of a series of trades disclosed by MLAB executives, including other transactions by John Sakys, the CFO.
Insider Buying and Selling at Mesa Laboratories, Inc.
Insider activity at MLAB on June 15, 2026, was notable. Brian Archbold, SVP Operations, sold a total of 2,454 shares, while CFO John Sakys was active with multiple transactions. Sakys bought 2,717 shares at $104.08 and made several other trades on the same day.
Other Institutional Activity in MLAB
There's been significant institutional movement in MLAB. Long Path Partners LP increased its stake by 178,360 shares, now holding 405,583 shares valued at about $35.9 million. BlackRock, Inc. reduced its position by 4,815 shares, ending with 393,851 shares worth approximately $34.8 million. Boston Partners added 55,335 shares to hold 268,711 shares valued at $23.8 million. Select Equity Group, L.P. also increased its holdings by 29,450 shares, closing with 235,885 shares valued at $20.9 million.
Mesa Laboratories, Inc. Stock Down 19.3%
MLAB shares are trading around $104.08. Although specific financial metrics like market cap and P/E ratio are not available, the stock's activity suggests robust trading interest. The peer activity indicates varied institutional confidence in the stock's performance.
$MLAB stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Analysts have been actively updating their views on MLAB. On February 4, 2026, Wells Fargo maintained a 'hold' rating with a price target of $94. Evercore ISI previously maintained a 'buy' rating with a target of $106. The consensus among analysts remains mixed, reflecting differing outlooks on MLAB's future performance.
Bottom Line
Insider sales, like those by Brian Archbold, provide insight into executive sentiment at MLAB. Institutional investors show varied confidence levels, with some increasing and others reducing their stakes. Analyst ratings suggest a cautious outlook, with mixed recommendations from key firms. As always, these insights reflect past actions and may not indicate current positions or future performance.
Get Mesa Laboratories, Inc. alerts
New 13F filings, insider trades, and analyst moves on $MLAB, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.